45 results about "Receptor expression" patented technology

The present invention relates to novel cell lines for the expression of the human LHCG receptor and for the expression of the human LHCG receptor and a luciferase reporter gene. Methods for producing such cell lines are also described. The cell lines of the present invention, which express the LHCG receptor and a luciferase reporter gene, can be used in methods for determining the presence and biological activity of r-hLH and r-hCG samples.

The present invention inter alia relates to a T-cell expressing a chimeric CD 95 receptor comprising a polypeptide, wherein said polypeptide comprises at least one CD 95-derived polypeptide region having at least 60% sequence identity with a polypeptide domain, a polypeptide region or a polypeptide motif of a human CD 95 wildtype receptor, wherein said human CD 95 polypeptide region comprises a CD 95 extracellular ligand binding domain; further wherein said polypeptide comprises at least one non-CD 95-derived co- stimulatory cytoplasmic polypeptide domain, region or motif of a tumor necrosis factor receptor superfamily protein comprising CD40, CD40L, CD27, HVEM, GITR, CD30, OX40, and / or LTBR, an immunoglobulin superfamily (IgSF) protein, a Toll-like-receptor, and / or an IL6-receptor family protein; wherein the T-cell further expresses an engineered T-cell receptor. The present invention also relates to a vector comprising nucleic acids encoding for the CD 95 receptor and the engineered T-cell receptor, as well as to a kit for preparing the T-cells of the present invention, and a pharmaceutical composition comprising the T-cells. The invention also relates to a method for preparing a T-cell for immunotherapy, and to a method for treating a patient having a disease comprising administering the pharmaceutical composition.

This invention discloses a composition and method comprising bis(demethoxycurcumin) enriched in at least 20% w / w for inhibiting receptor for advanced glycation end products (RAGE) expression in subjects with chronic inflammatory conditions. The composition further comprises β-amyrin palmitate (BAP). This invention also discloses the use of the above composition in controlling chronic inflammatory conditions in subjects.

The present invention relates to NK cells expressing dual-targeting chimeric antigen receptors for CD19 and CD22, and uses thereof. In the present invention, it was found that the delivery efficiency of a CAR expression vector and the production efficiency of CAR-NK cells are excellent when, among the cell surface proteins of PBMCs for producing CAR-NK cells (UCI-101), CD16 is expressed at 70% or less, natural killer group 2D (NKG2D) is expressed at less than 10%, CD57 is expressed at 30% or less, low-density lipoprotein receptor (LDLR) is expressed at 0.1% or more, and natural cytotoxicity triggering receptor 3 (NKp30) is expressed at less than 10%. In addition, optimal conditions for inducing NK cell differentiation and optimal conditions for transduction, under which the delivery efficiency of a CAR expression vector and the production efficiency of CAR-NK cells are excellent, were established, and CAR-NK cells produced by the method according to the present invention were found to exhibit an excellent antitumor effect in an animal model, and thus can be effectively used as a composition for preventing or treating diseases related to CD22 (or CD19) expression or diseases related to B cells.

The application discloses a composition for inducing T cell reprogramming into NK-like cells and application thereof. The composition comprises a DNA methyltransferase inhibitor, a histone deacetylase inhibitor and a vitamin C phosphate derivative; the molar ratio of the DNA methyltransferase inhibitor and the vitamin C phosphate derivative is 1: (40-2500); and the final concentration of the histone deacetylase inhibitor is 0.05-2 muM. The vitamin C phosphate derivative is used to replace common vitamin C, and the defects of common vitamin C, such as weak reprogramming promotion effect in a platelet lysate system, limited cell proliferation and low receptor expression, are overcome, so that the composition is more suitable for a clinical serum-free large-scale preparation scene.

To provide a novel composition capable of promoting expression of a pleiotrophin receptor.SOLUTION: An agent for enhancing pleiotrophin receptor expression comprising, as an active ingredient, one or two or more plant extracts of plants selected from the group consisting of Ruscus aculeatus, Olea europaea, and Plantago major.SELECTED DRAWING: Figure 2

The present application relates to the use of amphotericin B or its combination in the preparation of anti-tumor drugs. The present application first confirms that amphotericin B directly binds to Toll-like receptor 2 and activates the downstream signaling pathway as a Toll-like receptor 2 agonist, thereby enhancing the phagocytic ability of macrophages to tumor cells; it is first confirmed that amphotericin B combined with therapeutic antibodies can produce a synergistic anti-tumor effect, and the above synergistic effect is mainly due to the regulatory effect of amphotericin B on macrophage function, including enhancing Fc gamma receptor expression and polarizing macrophages to M1 direction, which provides a solid foundation for the clinical transformation of amphotericin B and is expected to provide new treatment options for cancer patients.

Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a Receptor for Advanced Glycation End-products (AGER or RAGE) gene. The RAGE RNAi agents and RNAi agent conjugates disclosed, herein inhibit the expression of an AGER gene. Pharmaceutical compositions that include one or more RAGE RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described RAGE RNAi agents to pulmonary cells, in vivo, provides for inhibition of AGER gene expression and a reduction in membrane RAGE activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including pulmonary inflammation diseases such as severe asthma.

The present invention relates to methods for identifying cancer, responders, predicting response and stratifying patients with respect to a combination therapy comprising the administration of a P2X4 receptor inhibitor and a cell death inducing chemotherapy. The methods according to the present invention are based on the detection of P2X4 receptor protein expression in cells of a patient-derived cancer sample, e.g. cells or organoids, to identify cancer, responders, predict responders and stratify patients, wherein an increase in protein expression identifies cancer, responders and predicts responders when applying the combination therapy and also allows to stratify the patients accordingly.

The invention discloses a CCK2R ligand compound, a radiolabeled compound and application thereof, and relates to the technical field of biological medicine. Wherein the structural general formula of the CCK2R ligand compound is shown in the specification; wherein R is a chelating group, and n is an integer from 3 to 5. The CCK2R ligand compound has good CCK2R binding capacity, compared with a tracer agent or a therapeutic agent in the prior art, the radiolabeled compound composed of the CCK2R ligand compound and radionuclide has equivalent or even higher uptake value on tumors expressed by cholecystokinin II type receptors, the in-vivo inhibition effect is remarkable, and the CCK2R ligand compound can be used for preparing the radiolabeled compound for treating the tumors expressed by the cholecystokinin II type receptors. And a new strategy is provided for diagnosis and treatment of tumors with cholecystokinin II type receptor expression.

The invention belongs to the technical field of biology, and discloses an influenza B virus sensitizing cell strain as well as a construction method and application thereof. The influenza B virus sensitizing cell strain STX-BB2 can be used for stably expressing influenza virus receptor ST6GAL1 protein in a human source and controllably inducing and expressing influenza B virus PB2 protein by using doxycycline; the preservation number of the cell strain STX-BB2 is GDMCC (China General Microbiological Culture Collection Center) NO: 67100; the cell strain can enhance the expression ability of a host receptor and the virus replication key gene level at the same time; the infection efficiency and the replication titer of the influenza B virus in MDCK cells can be improved; the method can be widely applied to influenza B virus separation, mechanism research, vaccine seed virus amplification and drug screening model construction.

The present invention, as described herein, relates to a novel cell line for expressing the human FSH receptor together with a luciferase reporter gene. Methods for preparing such cell lines are also described. The cell lines of the present invention expressing the FSH receptor and luciferase reporter gene can be used in methods for determining the presence and biological activity of r-FSH samples.

Provided herein are oligonucleotides for inhibiting the expression of Activin receptor 2B (ACVR2B) and methods of using the oligonucleotides for reducing ACVR2B expression in a subject.

The present invention relates to a humanised sequence binding the receptor tyrosine kinase ErbB3 / HER3 for the generation of anti-ErbB3 / HER3 antibodies in different formats, such as, for example, immunoglobulins, bispecific antibodies, in particular bispecific T-cell engagers, or antibody-drug conjugates (ADCs) or fusion immunoproteins, for the treatment of solid tumours depending on the expression of the ErbB3 receptor.

This invention discloses a radioactive triazolidinedimethylpyrimidine derivative, its preparation method, and its applications. The derivative has the structure shown in Formula I. Compared with the prior art, this invention provides a class of high-affinity adenosine A derivatives. 2A Radioactive triazolidinedimethyl derivatives of the receptor. This class of compounds belongs to the diagnostic category A. 2A Novel compounds for receptor-related diseases, and derivatives thereof prepared to target A 2A Imaging of the receptor, compared with previously reported targeting of A 2A Compared to receptor-specific radiopharmaceuticals, the radioactive compounds of this invention can rapidly reach equilibrium in the brain, thereby facilitating A. 2A Rapid quantification and qualitative analysis of receptors. The compounds of this invention can be applied not only to A... 2A The diagnosis of receptor-related brain diseases can also be applied to A 2A Diagnosis and efficacy evaluation of tumors with high receptor expression.

This invention discloses the application of the FAM26F gene in the diagnosis and treatment of depression, belonging to the interdisciplinary field of molecular biology and neuropsychiatry. This invention reveals for the first time that downregulation of the FAM26F gene expression disrupts glutamate homeostasis by affecting the expression of glutamate transporters and receptors, thereby leading to depressive-like behaviors. Based on this, this invention provides two core applications: first, the application of the FAM26F gene in the preparation of diagnostic products for depression, achieving objective diagnosis by detecting the expression level of this gene in samples such as peripheral blood; second, the application of the FAM26F gene in the preparation of therapeutic drugs for depression, wherein the drug uses a gene therapy vector that upregulates the expression of this gene as its active ingredient, and is administered via lateral ventricle injection or nasal nebulization, effectively reversing depressive-like behaviors in animal models. This invention provides a novel, precise diagnostic target and targeted treatment strategy for depression.

The invention provides a culture medium for maintaining expression of key receptors of breast cancer organs and a preparation method of the culture medium. The culture medium comprises the following components: a basic culture medium, 1.25 to 2 mM of N-acetyl-L-cysteine, 1 * of N2, 1 * of B27, 1 * of Glutamax, 10 mM of HEPES, 1 [mu] M of SB202190, 5 to 10 mM of nicotinamide, 0.5 to 1 [mu] M of A83-01, 5 [mu] M of Y27632, 0.1 to 1 [mu] M of Verteporfin, 10 [mu] M of Sovesudil, 50 to 100 ng / mL of R-Spondin, 250 ng / mL of Noggin, 5 ng / mL of EGF, 5 ng / mL of Neuregulin 1, 200 ng / mL of The culture medium for maintaining the expression of the key receptor in the breast cancer organoid realizes stable maintenance of the expression of the key receptor in the breast cancer organoid, and provides a more accurate and reliable organoid model for research and treatment of breast cancer.

This invention discloses a method for detecting the killing effect of multiple HLA-specific T cells, belonging to the field of biotechnology. This invention enables T2 cells to express various HLA-I molecular subtypes. After the receptor is expressed, antigen fragments loaded with various HLA-I molecules can be captured in the culture supernatant for in vitro evaluation of the killing effect of HLA-I-adapted antigen-specific T cells, thus expanding the application of T2 cells in in vitro killing effect evaluation. Simultaneously, it avoids the enormous workload and high cost of using the K562 cell line to construct a cell line for each HLA subtype-specific antigen fragment during the HLA subtype construction process.

The invention relates to the technical field of biotechnology and cell engineering, in particular to a large-scale culture method of central memory T cells (TCM). According to the method, the lymphocyte expressed by the high homing receptor is activated by adopting an alternating electric field, and the cell activity is improved by combining with a composite metabolism regulator. A two-photon excitation three-dimensional scaffold of a modified collagen peptide, ferroferric oxide and a quantum dot labeled organoid is utilized to simulate an in-vivo microenvironment to promote cell anchoring. And finally, through gene editing, engineering a cryopreservation system of saccharomyces cerevisiae and ultraviolet light activated autophagic peptide, so as to realize the enhancement of cell function stability and long-term memory characteristic. According to the invention, the limitation of traditional two-dimensional culture is broken through, and an efficient and controllable T cell preparation scheme is provided for tumor immunotherapy, autoimmune disease regulation and personalized cell therapy through systematic integration of physical field regulation, bionic scaffold design and genetic engineering means.

The invention provides a construction method and application of siRNA for inhibiting expression of a canine APN receptor, and belongs to the field of gene engineering. According to the method, siRNA is connected to a saRNA vector. The invention also provides a method for interfering the expression of the canine APN receptor and application of the method in inhibiting canine coronavirus infection. The siRNA is connected with the saRNA vector, expression of APN in mouse blood can be continuously inhibited, and the silencing time is prolonged to 150 days while the silencing effect of the APN in the mouse blood is maintained.

The application discloses application of SLC2A1 in treatment of paracetamol-induced acute liver injury, and the drug comprises a substance for up-regulating Slc2a1 gene or enhancing SLC2A1 protein level. SLC2A1 expression plays a key role in the disease progression of acute liver injury, and a small molecule compound AS1949490 can increase the level of SLC2A1, thereby promoting the expression of liver macrophage efferocytosis receptors, so as to activate efferocytosis. In addition, AS1949490 can also significantly reduce the increase of ALT and AST contents of the liver caused by paracetamol-induced acute liver injury, and reduce the liver injury area.

This application belongs to the field of bovine colostrum peptide technology, and relates to a bovine colostrum active polypeptide with antioxidant and sleep-aiding effects, its preparation method, and its application. The bovine colostrum active polypeptide contains at least one of HQPHQPLPPT, AVPYPQ, HLPIP, VVPPF, YPVEP, or FPPQ. The prepared bovine colostrum active polypeptide exhibits important biological activities: on the one hand, it exerts antioxidant effects by scavenging / inhibiting ABTS free radicals; on the other hand, it inhibits neuronal excitability, regulates the sleep-wake cycle, and improves insomnia by promoting the expression of the inhibitory neurotransmitter GABA and its receptor, as well as 5-hydroxytryptamine synaptic signaling. In terms of flavor, the bovine colostrum active polypeptide has no obvious bitterness or astringency. Furthermore, the preparation method of the bovine colostrum active polypeptide requires low equipment requirements, is simple and easy to operate, and is suitable for large-scale industrial production. This application enriches the bioactive peptide library and is of great significance for promoting technological progress and industrial upgrading in the field of bovine colostrum peptides.

The invention provides a biomarker for pathological staging judgment of primary biliary cholangitis and application of the biomarker, and belongs to the technical field of biomarkers. The biomarker disclosed by the invention comprises a peroxisome bifunctional enzyme, phosphoenolpyruvate carboxykinase, a receptor expression enhancing protein 6, an HLA (human leukocyte antigen) II histocompatibility antigen gamma chain and a C-X-C motif chemotactic factor 10. According to the method, the improvement of the PBC diagnosis efficiency is taken as a starting point, the serum protein and the N-glycopeptide are taken as screening templates, a more accurate non-invasive PBC pathological staging judgment method is provided, and a theoretical basis is provided for early diagnosis of PBC.

The present invention relates to novel, selective, radiolabelled compound having monoacylglycerol lipase (MGL) affinity which are useful for imaging and quantifying MGL receptor expression, distribution and enzyme occupancy in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, the use of such compounds and compositions for imaging a tissue, cells or a host, in vitro or in vivo and to precursors of said compounds.

The present disclosure provides novel polypeptide-therapeutic compound or hormone-therapeutic compound conjugates using cleavable or non-cleavable linkers, whereby the polypeptide or hormone serves to target specific cells using receptor expression on the targeted cell to bind the ligand (polypeptide or hormone) carrying the therapeutic compound unlike antibody drug conjugates. Upon binding, the ligand and the therapeutic compound (multiples of the therapeutic compound in some embodiments) enter the cell by receptor-mediated endocytosis, and release drugs conjugated to the ligand by linkers, to interact with intracellular components to enhance, restore, or block a signal transduction process. The ligands for the polypeptide-therapeutic compound or hormone-therapeutic compound conjugates include, but are not limited to: cytokines, growth factors and hormones among other proteins with corresponding cell surface specific receptors. The disorders targeted by such polypeptide-therapeutic compound or hormone-therapeutic compound conjugates include, but are not limited to: immunological disorders (e.g., allergy and autoimmune disorders) and cancer.

The invention described herein relates to novel cell lines for the expression of both human FSH receptor and luciferase reporter gene. Also described herein are methods of making such cell lines. The cell lines expressing FSH receptors and luciferase reporter genes of the invention can be used in methods for detecting the presence of r-FSH samples and their biological activity.

Provided are a TIGIT and OX40-based enhanced receptor (TIGIT / OX40) capable of increasing the activation level and survival time of immune cells, and an immune cell modified to express the enhanced receptor. Also provided is an immue cell modified to express two different enhanced receptors containing the enhanced receptor.

The invention discloses a tumor animal model construction method for simulating clinical metastasis characteristics, and relates to the technical field of biological medicine. Comprising the following steps: S1, modifying a CXCR4 chemokine receptor of a tumor cell: modifying a target tumor cell by adopting a CRISPR-Cas9 technology; high-efficiency targeting of tumor metastasis is realized through double mechanisms of CXCR4 gene precise modification and target organ microenvironment directional regulation and control: on one hand, a CRISPR-Cas9 technology is used for editing a CXCR4 gene key functional region, so that the receptor expression quantity is stably increased by 2-5 times, and the chemotactic response capability of tumor cells is enhanced; on the other hand, recombinant human SDF-1alpha is locally injected, a specific chemotactic signal gradient is constructed for a target organ, the final model can achieve the effects that the number of target organ transfer lesions is larger than or equal to 5 / organ, the non-target organ transfer rate is smaller than or equal to 10%, the clinical transfer rule is strictly followed, the clinical'primary lesion-target organ 'transfer path is accurately reengraved, and the target organ transfer rate is smaller than or equal to 10%. And the defects of random transfer and poor target organ specificity of the traditional model are thoroughly improved.

Provided herein are populations of IL2 dependent cells that express high affinity CD16 but do not express IL-2. The cells maintain stable expression of the Fc receptor CD16 while maintaining cytotoxicity. In some embodiments, the expression level of CD16 when the cell is activated is reduced by no more than 20% compared to the expression level of CD16 on the cell prior to activation. Also provided are compositions and kits comprising the cells, as well as methods of making and using IL2 dependent cells.

The invention discloses application of shikimic acid in preparation of anti-deep vein thrombosis drugs for regulating and controlling Prdx1 + neutrophil, in-vivo experiments prove that the shikimic acid can obviously relieve the thrombus load of deep vein thrombosis (DVT) model mice, and the shikimic acid is dose-dependent, so that the shikimic acid can be applied to preparation of anti-deep vein thrombosis drugs for regulating and controlling Prdx1 + neutrophil, and the application of the shikimic acid to preparation of anti-deep vein thrombosis drugs for regulating and controlling Prdx1 + neutrophil. More importantly, the invention discloses shikimic acid under single cell resolution for the first time by adopting a single cell RNA sequencing technology, and by up-regulating the proportion and quantity of Prdx1 + neutrophile granulocyte subgroups in thrombus tissues and inhibiting expression of receptors related to thrombus formation on the surfaces of the subgroups, so that formation of neutrophile granulocyte-platelet aggregates is reduced, and the anti-DVT effect of the shikimic acid is exerted. The discovery not only provides a solid experimental basis for clinical application of shikimic acid in DVT prevention, but also provides brand-new and accurate immunological interpretation for the action mechanism of shikimic acid.